Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

Table 3

Clinical efficacy.

	CR	PR	SD	PD	ORR
Control group ()	0	15	14	21	15
Study group ()	0	19	20	11	19
					4.596
					0.032

CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; ORR: objective remission rate.